Detalhe da pesquisa
1.
Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas.
Blood
; 137(21): 2947-2957, 2021 05 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33259592
2.
Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations.
Cancer Discov
; 14(5): 846-865, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38456804
3.
Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners.
Mol Cancer Ther
; 22(5): 630-645, 2023 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36912782
4.
Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition.
Mol Cancer Ther
; 20(6): 1080-1091, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33785652
5.
Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy.
Commun Biol
; 4(1): 112, 2021 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33495510
6.
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib.
Mol Cancer Ther
; 20(2): 238-249, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33273059
7.
AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells.
Clin Cancer Res
; 26(4): 922-934, 2020 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31699827
8.
AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia.
Clin Cancer Res
; 26(24): 6535-6549, 2020 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32988967
9.
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.
Nat Commun
; 10(1): 5065, 2019 11 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31699977
10.
BRD4 facilitates replication stress-induced DNA damage response.
Oncogene
; 37(28): 3763-3777, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29636547
11.
BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors.
PLoS One
; 13(7): e0200826, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30036377
12.
Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer.
Cancer Res
; 78(23): 6691-6702, 2018 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30297535
13.
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.
Nat Commun
; 9(1): 5341, 2018 12 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-30559424
14.
Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer.
Cancer Res
; 65(22): 10423-30, 2005 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16288033
15.
AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
Mol Cancer Ther
; 15(11): 2563-2574, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27573426
16.
The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.
Clin Cancer Res
; 21(12): 2811-9, 2015 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25779944
17.
MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis.
PLoS One
; 9(10): e108371, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25289887
18.
Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
Mol Cancer Ther
; 12(8): 1442-52, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23699655
19.
Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism.
Cancer Res
; 68(2): 561-70, 2008 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18199553